MedDataX Logo

Role of PET/MRI in Head and Neck Cancer

NCT ID: NCT04360993

Last Updated: 2020-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-12

Study Completion Date

2020-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study aim was to investigate the diagnostic role of Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) in head and neck cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was assessed the role of Diffusion weighted imaging (DWI) in discriminating between benign and malignant lesions in Head and neck cancer as well as studying the relationship between glucose metabolism (18F-FDG) and Apparent diffusion coefficient (ADC) for better tumor assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer Benign Neoplasm Malignant Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients underwent PET/CT & PET/MRI

Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up

Radiotherapy

Intervention Type RADIATION

Patients have received radiotherapy as a treatment modality for Head and neck cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiotherapy

Patients have received radiotherapy as a treatment modality for Head and neck cancer

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Proved Head and neck cancer
* Underwent PET/CT and PET/MRI
* Lymph nodes due to primary Head and neck cancer.

For healthy subject:

* No previous history of malignancy.
* no inflammation or infection in the neck region.
* lymph node size \<10mm.

Exclusion Criteria

* patients treated before by radiotherapy / chemoradiotherapy
* patients underwent surgery
* artifacts
Minimum Eligible Age

41 Years

Maximum Eligible Age

88 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pecs

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Omar Freihat

Clinical investigator.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arpad Kovacs, MD, PhD

Role: STUDY_DIRECTOR

University of Pecs

Cselik Zsolt, MD, PhD

Role: STUDY_CHAIR

Csolnoky Ferenc Kórház, Veszprém, Hungary

Omar Freihat

Role: PRINCIPAL_INVESTIGATOR

Doctoral school of health sciences, Pécs University, Hungary

References

Explore related publications, articles, or registry entries linked to this study.

Freihat O, Toth Z, Pinter T, Kedves A, Sipos D, Cselik Z, Lippai N, Repa I, Kovacs A. Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC). Oral Oncol. 2021 May;116:105239. doi: 10.1016/j.oraloncology.2021.105239. Epub 2021 Feb 25.

Reference Type DERIVED
PMID: 33640578 (View on PubMed)

Freihat O, Pinter T, Kedves A, Sipos D, Cselik Z, Repa I, Kovacs A. Diffusion-Weighted Imaging (DWI) derived from PET/MRI for lymph node assessment in patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Cancer Imaging. 2020 Aug 8;20(1):56. doi: 10.1186/s40644-020-00334-x.

Reference Type DERIVED
PMID: 32771060 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pécs/ Oncoradiology

Identifier Type: -

Identifier Source: org_study_id